Organization | Lumbini Medical College

Lumbini Medical College Report issue

Academic/Hospital Phase 4

Founded: Tansen Nepal

Organization Overview

First Clinical Trial

2018

NCT03620513

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

Lumbini Medical College

Active Ingredients

Drugs in Phase 4 Trials (5)

cetirizine (zyrtec) (1 trial)

fluticasone (cutivate) (1 trial)

lidocaine (xylocaine) (1 trial)

oxymetazoline (ocuclear) (2 trials)

prednisolone (hydeltra) (1 trial)

Drugs in Other Trials (2)

bupivacaine (Exparel) (1 trial)

epinephrine (levophed) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Otitis (Phase 4)

Otitis Media (Phase 4)

Otitis Media with Effusion (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial APIs: 7